Remove tag personalised-care
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Personalising marketing content. Virtual connections. Content consistency.

article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

The unmet needs can be grouped into the broad categories of efficacy-related needs, cost-related needs, toxicity-related needs, personalised care-related needs, and “other” needs. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

This gives them huge amounts of customer data that allows them to shape and personalise the way they engage with their customers, not least thanks to the direct-to-consumer sales model they often offer. Jeremy Richter, Tag. Joe adds: “Digitally-native brands also have a laser focus on the channels they’re executing for.

article thumbnail

What is modular content and why do pharma marketers need it NOW?

pharmaphorum

Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. The post What is modular content and why do pharma marketers need it NOW?

article thumbnail

A roadmap for adopting New Science 

pharmaphorum

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. billion and $6.7 People simply can’t afford them. But there is a silver lining.